SOUTH SAN FRANCISCO, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced data from the first three of five potential cohorts of its ongoing Phase 1 dose ...
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today ...
Designation encompasses treatment of pancreatic cancer, including use in combination with immune checkpoint inhibitors NEW YORK, Jan. 12, 2026 /PRNewswire/ -- Novita Pharmaceuticals, Inc. ("Novita"), ...
Assessing the impact of scalp cooling in patients receiving trastuzumab deruxtecan for metastatic breast cancer. First-line durvalumab plus chemotherapy with or without oleclumab for locally advanced ...
In 30 metastatic NSCLC patients who progressed on PD-1/PD-L1 inhibitors, the triple IO combo regimen at median follow-up time of 11.5 months achieved a DCR of 89.3% and Median PFS of 8.6 months ...
Survival and safety of two year-fixed duration vs continuous immune checkpoint inhibitor therapy in advanced or metastatic NSCLC: A systematic review. This is an ASCO Meeting Abstract from the 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results